April 18, 2017
Ryan S. Pawell
CEO, Indee
Cell-derived gene therapies (CDGTs) – cell-based therapies requiring an intracellular delivery step – offer the opportunity to radically impact patient outcomes across several challenging disease areas. A potential limitation in the application and distribution of these therapies is their ability to be manufactured in a scalable and affordable manner.
Indee is working to address this problem by developing an intracellular delivery platform that scales up and out to meet the demands of the diseased patient populations by delivering functional macromolecules (DNA, RNA, endonucleases, etc.) to therapeutically relevant cell types (HSCs, iPSCs, TCells, etc.).
Ryan Pawell is an Eagle Scout, engineer, inventor and scientist turned biotech entrepreneur. He is an alumni of Y Combinator’s Winter 2017 cohort and recently submitted his PhD on biomicrofluidics. Ryan is a graduate the NSW Health Ignition Medical Program. He completed a BSci Mechanical Engineering at UC Santa Barbara while working with NuVasive and Inogen on medical device development. More recently, Ryan raised a meaningful amount of both private and venture financing to develop biomicrofluidic devices for scalable cellular engineering.
